Gilead Sciences
American biopharmaceutical company
GILD Nasdaq
ISIN US3755581036 SEC CIK 882095 LEI 549300WTZWR07K8MNV44
Follow Gilead Sciences
Weekly email: filings, results
Revenue, last quarter
$8.3B
+6.8% vs same quarter last year
Net income
$2.4B
−20.4% vs same quarter last year
EPS, diluted
$1.94
−20.2% vs same quarter last year
Operating cash flow
$5B
+22.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $29.4B | $8.5B |
| FY24 | $28.8B | $480M |
| FY23 | $27.1B | $5.7B |
| FY22 | $27.3B | $4.6B |
| FY21 | $27.3B | $6.2B |
| FY20 | $24.7B | $123M |
| FY19 | $22.4B | $5.4B |
| FY18 | $22.1B | $5.5B |
| FY17 | $26.1B | $4.6B |
| FY16 | $30.4B | $13.5B |
| FY15 | $32.6B | $18.1B |
| FY14 | $24.9B | $12.1B |
| FY13 | $11.2B | $3.1B |
| FY12 | $9.7B | $2.6B |
| FY11 | $8.4B | $2.8B |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 78.8% | 34% | 28.9% |
| FY24 | 78.3% | 5.8% | 1.7% |
| FY23 | 76% | 28% | 20.9% |
| FY22 | 79.3% | 26.9% | 16.8% |
| FY21 | 75.8% | 36.3% | 22.8% |
| FY20 | 81.5% | 16.5% | 0.5% |
| FY19 | 79.2% | 19.1% | 24% |
| FY18 | 78.1% | 37.1% | 24.7% |
| FY17 | 83.3% | 54.1% | 17.7% |
| FY16 | 86% | 58% | 44.4% |
| FY15 | 87.7% | 68% | 55.5% |
| FY14 | 84.8% | 61.3% | 48.6% |
| FY13 | 74.5% | 40.4% | 27.5% |
| FY12 | 74.5% | 41.3% | 26.7% |
| FY11 | 74.7% | 45.2% | 33.4% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $9.5B |
| FY24 | $10.3B |
| FY23 | $7.4B |
| FY22 | $8.3B |
| FY21 | $10.8B |
| FY20 | $7.5B |
| FY19 | $8.3B |
| FY18 | $7.5B |
| FY17 | $11.3B |
| FY16 | $16.3B |
| FY15 | $20.5B |
| FY14 | $12.3B |
| FY13 | $3B |
| FY12 | $2.8B |
| FY11 | $3.5B |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | $4B | $1.9B |
| FY24 | $3.9B | $1.2B |
| FY23 | $3.8B | $1B |
| FY22 | $3.7B | $1.4B |
| FY21 | $3.6B | $546M |
| FY20 | $3.4B | $1.6B |
| FY19 | $3.2B | $1.7B |
| FY18 | $3B | $2.9B |
| FY17 | $2.7B | $954M |
| FY16 | $2.5B | $11B |
| FY15 | $1.9B | $10B |
| FY14 | $0 | $5.3B |
| FY13 | $0 | $582M |
| FY12 | - | $667M |
| FY11 | - | $2.4B |
- Gilead Sciences
- Healthcare median
Show the numbers
| Year | Gilead Sciences | Healthcare median |
|---|---|---|
| FY25 | 28.9% | −30.6% |
| FY24 | 1.7% | −47% |
| FY23 | 20.9% | −58% |
| FY22 | 16.8% | −80.4% |
| FY21 | 22.8% | −71.9% |
| FY20 | 0.5% | −62.2% |
| FY19 | 24% | −46.3% |
| FY18 | 24.7% | −49.6% |
| FY17 | 17.7% | −45.9% |
| FY16 | 44.4% | −36% |
| FY15 | 55.5% | −38.4% |
| FY14 | 48.6% | −35.5% |
| FY13 | 27.5% | −37.1% |
| FY12 | 26.7% | −29.1% |
| FY11 | 33.4% | −27.9% |